ClinicalTrials.gg
RecruitingNCT06961968Updated Jan 12, 2026

Randomized Withdrawal Study in Patients With Schizophrenia

A Phase 3 interventional study of iloperidone and placebo in Schizophrenia, sponsored by Vanda Pharmaceuticals. Recruiting at 22 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing iloperidone in Schizophrenia — 2 open to participants now, 2 under way, 1 of them phase 3. iloperidone · Schizophrenia.

Planned enrollment
4th of 11
400 · median 260
Started
2025
the only one that year
Phase 3
4 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
7 of 11
Vanda Pharmaceuticals

Among the 11 studies testing iloperidone in Schizophrenia, this one is the 4th largest by planned enrollment, is the only one that started in 2025, is one of 4 in phase 3, and was the 11th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 11 studies testing iloperidone in Schizophrenia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About iloperidone

iloperidone: first FDA approval 2009 (FANAPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing iloperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Antipsychotic Agents
  • Iloperidone
  • Long-Acting Injection
  • Randomized Withdrawal
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females 18 to 65 years of age (inclusive)
  • Diagnosed with schizophrenia per criteria
  • In need of ongoing psychiatric treatment

Exclusion criteria

Exclusion Criteria:

  • diagnosis of a psychiatric disorder other than schizophrenia that was the primary focus of treatment within the previous six months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    iloperidone

    During the 12-week stabilization phase, all patients will receive open-label iloperidone administered as oral tablets (weeks 1-6) and as long-acting intramuscular injections (weeks 7-12). Subsequently, patients will be randomized in a 1:1 ratio to one of two arms: iloperidone long-acting injection or matching placebo. Post-randomization this arm will receive double-blind study drug (iloperidone long-acting injection) as long-acting intramuscular injections for up to 52 weeks.

    Drug: iloperidone

  • Placebo comparator
    placebo

    During the 12-week stabilization phase, all patients will receive open-label iloperidone administered as oral tablets (weeks 1-6) and as long-acting intramuscular injections (weeks 7-12). Subsequently, patients will be randomized in a 1:1 ratio to one of two arms: iloperidone long-acting injection or matching placebo. Post-randomization this arm will receive double-blind study drug (matching placebo) as long-acting intramuscular injections for up to 52 weeks.

    Drug: placebo

Interventions

  • iloperidone LAI

  • Drugplacebo

    matching placebo

06

What researchers measure

Primary outcomes

  1. Time to exacerbation of symptoms

    As measured by the time to first exacerbation of psychiatric symptoms

    Time frame: Up to 52 weeks post-randomization

07

Study locations

22 of 22 sites recruiting
  • Vanda Investigational Site
    Rogers, Arkansas 72758, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Costa Mesa, California 92626, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Lemon Grove, California 91945, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Oceanside, California 92056, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Pico Rivera, California 90660, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    San Diego, California 92123, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Walnut Creek, California 94596, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    North Miami, Florida 33161, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Atlanta, Georgia 30328, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Peachtree Corners, Georgia 30071, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Chicago, Illinois 60641, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Flowood, Mississippi 39232, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Saint Charles, Missouri 63304, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    St Louis, Missouri 63141, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Las Vegas, Nevada 89119, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Marlton, New Jersey 08053, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Staten Island, New York 10314, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Austin, Texas 78754, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Houston, Texas 77081, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Irving, Texas 75062, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Richardson, Texas 75080, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
  • Vanda Investigational Site
    Bellevue, Washington 98007, United States
    Recruiting
    • Vanda Pharmaceuticals · Contact202-734-3400
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2027, 30 months after the start.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's planned 30 months is close to that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 8, 2025
StartActual
May 14, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06961968
Responsible party
Sponsor
First posted
May 8, 2025
Start date
May 14, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jan 12, 2026

Study contacts

Vanda Pharmaceuticals Inc.
Contact
clinicaltrials@vandapharma.com
202-734-3400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iloperidone

Start the discussion